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Evaluation of impaired left ventricular (LV) filling has focused on intrinsic causes of LV dys-
function; however, pulmonary vascular changes may contribute to reduced LV filling and
dyspnea. We hypothesized that lower total pulmonary vascular volume (TPVV) on com-
puted tomography (CT) would be associated with dyspnea and decrements in LV end-dia-
stolic volume, particularly among ever-smokers.
Methods
The Multi-Ethnic Study of Atherosclerosis recruited adults without clinical cardiovascular
disease in 2000–02. In 2010–12, TPVV was ascertained as the volume of arteries and
veins in the lungs detectable on non-contrast chest CT (vessels 1 mm diameter). Car-
diac measures were assessed by magnetic resonance imaging (MRI). Dyspnea was self-
reported.
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Results
Of 2303 participants, 53% had ever smoked cigarettes. Among ever-smokers, a lower
TPVV was associated with a lower LV end-diastolic volume (6.9 mL per SD TPVV), stroke
volume, and cardiac output and with dyspnea (all P-values <0.001). Findings were similar
among those without lung disease and those with 0–10 pack-years but were mostly non-sig-
nificant among never-smokers. TPVV was associated smaller left atrial volume but not with
LV ejection fraction or MRI measures of impaired LV relaxation. In a second sample of ever-
smokers, a lower pulmonary microvascular blood volume on contrast-enhanced MRI was
also associated with a lower LV end-diastolic volume (P-value = 0.008).
Conclusion
Reductions in pulmonary vascular volume were associated with lower LV filling and dyspnea
among ever-smokers, including those without lung disease, suggesting that smoking-
related pulmonary vascular changes may contribute to symptoms and impair cardiac filling
and function without evidence of impaired LV relaxation.
Introduction
Heart disease and chronic obstructive pulmonary disease (COPD) are the first and third lead-
ing causes of morbidity and mortality in the world [1, 2]. Heart failure with preserved ejection
fraction (HFpEF) is an increasingly common diagnosis with significant clinical implications
and few therapies [3]. HFpEF and COPD both contribute to dyspnea and are frequently diag-
nosed in the same patient [4].
Evaluation of impaired left ventricular (LV) filling, a cardinal feature of HFpEF, has focused
on intrinsic causes of LV dysfunction [5]. Given the high cross-sectional area and flow in the
pulmonary circulation, minor but diffuse pulmonary vascular damage may decrease LV filling
and impair gas exchange, contributing to dyspnea and a potential misdiagnosis of HFpEF.
Alternatively, intrinsic impairment of LV relaxation would be expected to result in larger pul-
monary vascular volumes. However, whether subclinical pulmonary vascular differences are
associated with impaired LV filling in the general population is unknown.
Pulmonary vascular changes occur in emphysema, as it is defined by destruction of alve-
olar walls that include pulmonary capillaries [6]. We previously demonstrated in the general
population that the percentage of emphysema-like lung (percent emphysema) on CT was
associated with decreased LV filling [7] and dyspnea [8]. Lower lung function has also been
associated with reduced LV filling and the development of heart failure [9]. A smaller study
of smokers, mostly with COPD, showed that the loss of small pulmonary vessels on CT was
associated with greater percent emphysema and reduced six minute walk distance [10].
Whether pulmonary vascular changes are relevant outside of COPD and emphysema, how-
ever, is unclear.
We therefore performed full-lung CTs in a population-based cohort to test whether lower
total pulmonary vascular volume (TPVV) on CT is associated with impaired LV filling on
MRI and dyspnea. We hypothesized a priori that associations would be of greater magnitude
among ever-smokers. We also examined left atrial volume and MRI signs of LV relaxation.
Finally, we tested whether a contrast-enhanced MRI measure of pulmonary microvascular
blood volume was associated with lower LV filling in a second sample.
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Materials and methods
Multi-Ethnic Study of Atherosclerosis
The Multi-Ethnic Study of Atherosclerosis (MESA) is a prospective cohort study that recruited
6814 participants from six U.S. communities who were white, African-American, Hispanic or
Chinese-American and ages 45–84 years in 2000–02 and excluded those with clinical cardio-
vascular disease (angina, stroke or TIA, heart failure, atrial fibrillation, cardiac procedure),
undergoing treatment for cancer, pregnancy, weight over 300 pounds, a chest CT scan in the
prior year, cognitive inability or language barrier (other than English, Spanish, Cantonese or
Mandarin), and conditions impeding long term follow up (serious medical condition, living in
a nursing home, or plans to leave the community within five years) [11]. In 2010–12 4716 par-
ticipants returned for follow-up. All were invited to undergo cardiac MRI at baseline; the 75%
who did were invited to repeat it in 2010–12.
The MESA Lung Study enrolled 3965 MESA participants sampled randomly among those with
baseline measures of endothelial function, consent for genetic analyses and attended an examina-
tion during the recruitment period in 2004–06 [12], and a random sample in 2010–12 undergoing
cardiac MRI (S1 Fig); all were invited to undergo full-lung CT and spirometry in 2010–12.
The protocols of MESA and all studies described herein were approved by the Institutional
Review Boards of all collaborating institutions (Columbia University Medical Center Institu-
tional Review Board, the Johns Hopkins University School of Medicine Joint Committee on
Clinical Investigation, the University of Minnesota Human Research Protection Program, the
Northwestern University Social and Behavioral Sciences Institutional Review Board, the Har-
bor-University of California Los Angeles (UCLA) Research and Education Institute Human
Subjects Committee, the UCLA Office of Human Research Protection Program, the University
of Vermont Committees on Human Research, the Wake Forest University Health Sciences
Office of Research Institutional Review Board, and the University of Washington Human Sub-
jects Division) and the NHLBI. All participants provided written informed consent.
Total pulmonary vascular volume on CT
Non-contrast chest CTs were acquired at suspended full inspiration on 64-detector scanners
following the SPIROMICS protocol with reconstruction in 0.625–0.75mm increments by a
high-spatial contrast algorithm [13]. Trained readers used dedicated software (Apollo, VIDA
Diagnostics) to segment the lungs and pulmonary vessels with visual confirmation.
TPVV was measured within the segmented lung as the volume of arteries and veins, includ-
ing vessel walls and luminal blood, down to approximately 1 mm in diameter (Fig 1) [14]. The
intraclass correlation coefficient on 10% replicate reading was 1.0. Percent TPVV is TPVV
indexed to CT lung volume. The TPVV (mean of 130.7 cm3 or 70.7 cm3/m2 in this study) cap-
tures approximately 25–30% of the pulmonary blood volume estimated using invasive meth-
ods (250–300 cm3/m2) [15, 16]. This difference is not unexpected, given that the TPVV does
not capture the microvasculature (capillary blood volume, estimated as ~140 mL) [17], pre-
capillary arterioles and venules, and that the main, right and left pulmonary arteries and veins
were excluded from the TPVV but included in invasive measures.
Cardiac magnetic resonance imaging
MRI imaging was performed on 1.5T scanners with a phased-array surface coil [18]. Ana-
lysts blinded to participant information assessed LV mass, volumes and function using cine
steady-state free precession pulse sequence acquired on 2-chamber, 3-chamber, 4-chamber
and short-axis planes [19]. LV mass, end-diastolic and end-systolic volume measurements
Pulmonary vascular volume, impaired left ventricular filling and dyspnea
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used semiautomatic contouring (CIM6.0, UniServices) [20]. LV mass was determined at
end-diastole as epicardial minus endocardial volume times myocardial specific gravity [19].
Stroke volume was calculated as end-diastolic volume minus end-systolic volume, LV ejec-
tion fraction as stroke volume divided by end-diastolic volume, and cardiac output as stroke
volume times heart rate. The interobserver intraclass correlation coefficients were 0.96 for
end-diastolic volume, and for 0.95 for mass.
Left atrial volumes were measured using CVI42 software (Circle Cardiovascular Imaging
Inc.). Horizontal and vertical long-axis cine steady-state free precession images were used to
measure the biplanar left atrial volume in end-systole [(8 x vertical area x horizontal area)/(3π
x ((vertical length + horizontal length)/2))], excluding the pulmonary veins and left atrial
appendage. The interobserver intraclass correlation coefficient for left atrial volume was 0.96.
T1 mapping was performed on a subset to detect myocardial fibrosis [18].
Those eligible for gadolinium received an intravenous bolus of 0.15 mmol/kg (Magnevist,
Bayer Healthcare Pharmaceuticals) and diffuse fibrosis was evaluated before and after contrast
injection at 12 and 25 minutes on one short axis mid-slice using a modified Look-Locker inver-
sion recovery (MOLLI) sequence over a single breath-hold. The inversion recovery echo trig-
gered sequence was three inversion pulses at 100, 200 and 350 ms, and T1 mapping was per-
formed using MASS research software (Department of Radiology, Leiden University Medical
Fig 1. 3-dimensional reconstruction of the vessels comprising the total pulmonary vascular volume
and the lungs on CT scan. Colors depict the 5 lobes of the lungs; shaded region, the lung volume.
https://doi.org/10.1371/journal.pone.0176180.g001
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Center). The partition coefficient was calculated as the slope using 3 times points (ΔR1myocardium/
ΔR1blood), and the extracellular volume (ECV) as (partition coefficient x 100 x [1 –hematocrit])
[21]. Greater myocardial fibrosis by MRI is indicated by lower post-contrast T1 time and higher
ECV [22, 23].
LV circumferential diastolic strain (Δ length/mean length, %) was measured using the har-
monic phase method on four mid-ventricular segments from short-axis-tagged slices [24]. Peak
early diastolic strain rate was measured on strain-by-time curves as the peak rate of change in
early diastolic strain (%/msec). The strain relaxation index is the ratio of early/total relaxation
time divided by the peak early diastolic strain rate (msec/%) [25]. Lower peak early diastolic
strain rate and higher strain relaxation index indicate impaired myocardial relaxation.
In the second sample with measures of pulmonary microvascular blood volume on con-
trast-enhanced MRI, left atrial volumes were measured using multimodality tissue-tracking
software version 6.0 (Toshiba) [26]. RV parameters were measured using QMASS software
version 4.2 (Medis) [27]. Ostial pulmonary vein cross-sectional area was assessed using multi-
planar reformation software (Volume Viewer 15.10.4; General Electric) [28].
Pulmonary microvascular blood volume on MRI
Pulmonary microvascular blood volume was measured on contrast-enhanced MRI among 142
participants who were ages 50–79 years and had smoked at least 10 pack-years [29]. Pulmonary
microvascular blood flow and mean transit time were calculated from signal intensity-by-time
curves following a 0.1 mmol/kg gadolinium bolus on 3D-spoiled gradient-recalled echo images
at functional residual capacity. Pulmonary microvascular blood volume was calculated as blood
flow times mean transit time [29]. Measurements were obtained in the peripheral 2cm on 1cm
coronal slices. The mean pulmonary microvascular blood volume applied to the entire lung
(142cm3 [76.6cm3/m2]) was similar to Weibel’s morphological estimate of 140mL [17].
Respiratory symptoms
Trained interviewers assessed respiratory symptoms using standard questionnaires [30]. Dys-
pnea was defined as more breathlessness walking on level ground, hills or stairs compared to
those of same age, or breathlessness that causes one to stop walking, i.e., a modified Medical
Research Council score of 2 or greater [31]. Wheezing was defined as any wheeze within 12
months, and chronic cough as occurring for at least 3 of the past 12 months.
Covariate information
Age, sex, race/ethnicity, education and medical history were self-reported. Ever-smoking was
defined as over 100 lifetime cigarettes, current smoking as self-report of smoking within 30
days or urinary cotinine over 568 nmol/L [12], and pack-years as years smoking times packs/
day. Height, weight, blood pressure, fasting glucose, serum creatinine, total cholesterol, high-
density lipoprotein cholesterol (HDL-C) and triglycerides were measured using standard tech-
niques [32]. Hypertension was defined as blood pressure140/90 mmHg, or self-report and
antihypertensive medication use. Diabetes was defined as fasting glucose7.0 mmol/L or
hypoglycemic medication use. Resting arterial hemoglobin saturation was measured by pulse
oximetry (CMS-50F, Contec Medical Systems). Total body water was estimated by body com-
position scale (BCS-2, Valhalla Scientific). Physical activity was self-reported [33]. Agatston
coronary artery calcium score was calculated on gated cardiac CTs [34]. Medication inventory
assessed medication use [35].
Spirometry was conducted according to American Thoracic Society-European Respiratory
Society guidelines [36], using National Health and Nutrition Examination Survey III equations
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for predicted values (0.88 correction-factor for Chinese-Americans) [37]. Airflow limitation
was defined as pre-bronchodilator FEV1/FVC<0.7, and restrictive ventilatory defect as FVC
<lower limit of normal and FEV1/FVC>0.7. Percent emphysema was defined as the percent-
age of voxels below -950 Hounsfield units (HU) on full-lung CTs (Vida Diagnostics). Reference
equations defined emphysema on CT (percent emphysema above the upper limit of normal)
and predicted total lung volume on CT [38]. Lung regions between -600 and -250 HU were con-
sidered high attenuation areas on CT, reflecting subclinical interstitial lung disease [39].
Statistical analysis
Associations between TPVV and LV measures were estimated using generalized linear and
additive regression. Preliminary models adjusted for age, sex, race/ethnicity, height, weight,
education, CT manufacturer and milliamperes. Full models added smoking status, pack-years,
cardiac risk factors, creatinine, diuretic use, lung function and percent emphysema. Additive
interactions were tested in the full model for smoking history (ever vs. never), age, sex and
race/ethnicity. Missing data was minimal except for spirometry (11%) and pack-years (6%),
and was addressed by multiple imputation.
Associations between TPVV and respiratory symptoms were estimated using logistic
regression. Preliminary models adjusted for age, sex, race/ethnicity, height, weight, smoking
status, pack-years, CT manufacturer and milliamperes. Full models also included predictors of
dyspnea: lung function, percent emphysema and LV ejection fraction.
Statistical significance was defined by a two-tailed P-value <0.05. Analyses were performed
using SAS 9.3 (SAS Institute) and R package 3.2.3 (The R Project).
Results
Study participants
Of 4716 participants evaluated in 2010–12, 3136 underwent full-lung CT, of whom 2303 com-
pleted cardiac MRI and were included in analyses (S1 Fig). There were small differences in
demographics, smoking, percent emphysema and TPVV between included and excluded par-
ticipants (S1 Table).
Participants were a mean (±SD) age of 69±9 years (range 54–94), 49% male, 40% white,
27% African-American, 20% Hispanic and 14% Chinese-American. Fifty-three percent
reported ever smoking cigarettes, 10% currently smoked and 31% of ever-smokers reported
less than 10 pack-years. Twenty-seven percent had airflow limitation and 10% had emphysema
on CT. The mean TPVV was 130.7±34.9 cm3.
Ever-smokers were more likely to be white or African-American males, to have hyperten-
sion, airflow limitation, and greater LV mass index and LV mass/end-diastolic volume ratio
compared to never-smokers (Table 1). Percent TPVV was similar in the two groups; after
adjustment for CT manufacturer and milliamperes, percent TPVV tended to be lower in ever-
smokers compared to never-smokers (2.70 vs. 2.72; P = 0.11).
Across quintiles, lower values of percent TPVV were associated with greater age, BMI and
percent emphysema, white and Chinese-American race/ethnicity, current smoking, hyperten-
sion, diuretic use, airflow limitation (S2 Table).
Total pulmonary vascular volume and LV filling
Among all participants, a lower TPVV was associated with decrements in LV end-diastolic vol-
ume (fully-adjusted effect estimate -5.12mL/SD TPVV [95% CI, -6.80 to -3.43, P-value<0.001]).
Pulmonary vascular volume, impaired left ventricular filling and dyspnea
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Age, years 69.3±8.9 68.4±9.2
Male, no. (%) 719 (58.6) 398 (37.0)
Race/ethnicity, no. (%)
White 551 (44.9) 361 (33.5)
African-American 357 (29.1) 254 (23.6)
Hispanic 225 (18.4) 224 (20.8)
Chinese-American 93 (7.6) 238 (22.1)
Body mass index, kg/m2 28.3±5.0 27.5±5.2
Cigarette smoking status, no. (%)
Current smoker 220 (17.9) -
Former smoker 1006 (82.1) -
Pack-yearsa 26.6±26.2 -
10 or fewer pack-years, no (%) 337 (31.1) -
Greater than 10 pack-years, no (%) 747 (68.9) -
Hypertension, no. (%) 729 (59.5) 612 (56.8)
Systolic blood pressure, mmHg 122.4±19.8 123.3±19.6
Total cholesterol, mmol/L 4.65±1.0 4.87±0.9
HDL cholesterol, mmol/L 1.42±0.4 1.47±0.4
Triglycerides, mmol/L 1.23±0.7 1.24±0.7
Diabetes, no. (%) 222 (18.2) 186 (17.4)
Fasting glucose, mmol/L 5.6±1.4 5.5±1.3
Serum creatinine, μmol/L 82.2±22.1 76.9±26.5
Diuretic use, no. (%) 335 (27.3) 237 (22.0)
Airflow limitation, no. (%)b 352 (31.3) 208 (21.3)
Percent emphysema, median (IQR) 1.83 (0.69, 3.84) 1.11 (0.48, 2.54)
Percent predicted total lung volume on CT 1.05±0.18 1.02±0.16
Report of dyspnea on exertion, no. (%) 306 (25.0) 237 (22.2)
Report of wheezing, no. (%) 172 (14.0) 81 (7.5)
Report of chronic cough, no. (%) 135 (11.0) 85 (7.9)
TPVV, cm3 vessel 137.7±34.9 122.6±33.1
Percent TPVV, % of lung volume 2.70±0.27 2.71±0.26
Heart rate, bpmc 65.7±11.0 66.9±11.2
LV end-diastolic volume index, mL/m2 64.8±14.9 64.0±12.7
Stroke volume index, mL/m2 39.4±8.6 39.8±8.1
Cardiac index, L/min/m2c 2.6±0.6 2.6±0.6
LV mass index, g/m2 68.5±14.5 64.1±12.7
LV mass/end-diastolic volume ratio, g/mL 1.09±0.25 1.02±0.21
LV ejection fraction, % 61.4±7.4 62.5±7.1
Left atrial volume index, mL/m2d 36.4±11.1 36.3±11.0
Peak early diastolic strain rate, %/msece 0.11±0.06 0.13±0.06
Strain relaxation index, msec/%f 2.34±1.74 2.09±1.53
25-min post-contrast T1 time, msecg 520±40 518±43
Extracellular volume fraction, %h 26.8±3.1 26.9±3.0
Data are presented as no. (%) or mean±SD, except as noted. Abbreviations: HDL, high density lipoprotein;
IQR, interquartile range; TPVV, total pulmonary vascular volume.
a Among 1084 ever-smokers reporting pack-years.
b Airflow limitation defined as pre-bronchodilator FEV1/FVC <0.7.
c Among 1152 ever-smokers, 1018 never-smokers.
d Among 1056 ever-smokers, 943 never-smokers.
eAmong 997 ever-smokers and 1055 never-smokers.
fAmong 926 ever-smokers and 1000 never-smokers.
g Among 548 ever-smokers and 420 never-smokers.
h Among 238 ever-smokers and 169 never-smokers.
https://doi.org/10.1371/journal.pone.0176180.t001
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The association between TPVV and LV end-diastolic volume was modified by smoking history
(P-interaction = 0.03); results were therefore stratified by smoking.
Among ever-smokers, a lower TPVV was associated with decrements in LV end-diastolic
volume, stroke volume and cardiac output (Table 2). A lower TPVV was associated with a
lower LV mass and greater LV mass/end-diastolic volume ratio but not with LV ejection
fraction.
The association was similar among those with and without airflow limitation (Fig 2) and
emphysema (S2 Fig), and the association was approximately linear across TPVV values. Addi-
tionally, the association among those smoking 0–10 pack-years was of similar magnitude as
for those smoking more than 10 pack-years (S3 Fig). Results for percent TPVV were similar
(S3 Table).
Among never-smokers, there were smaller magnitude associations between TPVV and LV
end-diastolic volume and LV mass; findings were null for other LV parameters (Table 2).
Findings for LV end-diastolic volume among ever-smokers were consistent across strata of
sex, race/ethnicity, age, smoking, hypertension, diabetes and LV ejection fraction, with stron-
ger associations among current smokers and those without diabetes (S4 Fig). The association
was also significant among ever-smokers without asthma, without a restrictive ventilatory
defect and without a measured or self-reported lung disease (S4 Fig). Additional adjustment
for FEV1/FVC ratio, high attenuation areas on CT, LV ejection fraction, pulse oximetry, total
body water, physical activity, coronary artery calcium, and medication use had little impact on








LV end-diastolic volume, mL
Model 1 -4.44 (-6.64, -2.24) <0.001 -1.18 (-3.42, 1.06) 0.30
Model 2 -6.88 (-9.18, -4.58) <0.001 -2.71 (-5.18, -0.24) 0.03
Stroke volume, mL
Model 1 -3.08 (-4.41, -1.75) <0.001 -0.45 (-1.93, 1.02) 0.55
Model 2 -4.54 (-5.93, -3.15) <0.001 -1.46 (-3.08, 0.16) 0.08
Cardiac output, L/mina
Model 1 -0.15 (-0.24, -0.06) 0.002 -0.06 (-0.17, 0.05) 0.30
Model 2 -0.24 (-0.34, -0.14) <0.001 -0.10 (-0.22, 0.02) 0.09
LV mass, g
Model 1 -1.37 (-3.27, 0.52) 0.16 -0.73 (-2.69, 1.24) 0.47
Model 2 -4.65 (-6.59, -2.71) <0.001 -2.26 (-4.37, -0.14) 0.04
LV mass/end-diastolic volume ratio, g/mL
Model 1 0.029 (0.010, 0.048) 0.003 0.006 (-0.013, 0.025) 0.54
Model 2 0.025 (0.005, 0.044) 0.01 0.005 (-0.017, 0.026) 0.67
LV ejection fraction, %
Model 1 -0.41 (-0.99, 0.17) 0.16 0.51 (-0.17, 1.19) 0.14
Model 2 -0.51 (-1.14, 0.12) 0.12 0.32 (-0.44, 1.08) 0.41
Model 1: Adjusted for age, sex, race/ethnicity, height, weight, education, CT scanner manufacturer and milliamperes. Model 2: Additionally adjusted for total
cholesterol, high density lipoprotein cholesterol, triglycerides, hypertension, systolic blood pressure, diabetes, fasting glucose, creatinine, diuretic use,
percent predicted FEV1 and percent emphysema, as well as current smoking status and pack-years for ever-smokers
a Cardiac output available for 1152 ever-smokers and 1018 never-smokers.
https://doi.org/10.1371/journal.pone.0176180.t002
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the results (S4 Fig), while there was a greater magnitude association after adjustment for per-
cent predicted total lung volume on CT.
Total pulmonary vascular volume, left atrial volume, diastolic strain and
myocardial fibrosis
A lower TPVV was associated with lower left atrial volume overall (-3.28 mL/SD TPVV, P-
value<0.001) and among ever-smokers (S4 Table). There was no evidence for a relationship of
TPVV to peak early diastolic strain rate or strain relaxation index (S4 Table). Among ever-
smokers a lower TPVV was associated with a shorter post-contrast T1 time and a higher extra-
cellular volume (ECV) fraction, the latter significant only in the fully-adjusted model, while
results for never-smokers were non-significant (S4 Table).
Pulmonary microvascular blood volume and LV filling, left atrial volume
and pulmonary vein area
In a second sample of 142 ever-smokers, 56% of whom had COPD (full characteristics in S5
Table), lower pulmonary microvascular blood volume on MRI was associated with lower LV
end-diastolic volume, stroke volume and pulmonary vein area, and greater LV mass/end-dia-
stolic volume ratio (S6 Table). Results remained significant after adjustment for RV parameters.
Total pulmonary vascular volume and respiratory symptoms
Twenty-three percent of participants reported dyspnea, 11% reported wheezing and 9%
chronic cough. In the overall sample, a lower TPVV was associated with dyspnea in unadjusted
Fig 2. Generalized additive multivariate model of relationship between total pulmonary vascular volume and LV end-diastolic volume among
ever-smokers (A) without airflow limitation and (B) with airflow limitation. Results are adjusted for age, sex, race/ethnicity, height, weight, education,
CT scanner manufacturer and milliamperes, current smoking, pack-years, total cholesterol, high density lipoprotein cholesterol, triglycerides, hypertension,
systolic blood pressure, diabetes, fasting glucose, creatinine, diuretic use and percent emphysema. (Missing data for Fig 2 follows a single imputation
approach.) Panel A (Without airflow limitation): N = 771, P-linearity<0.001, P-nonlinearity = 0.59. Panel B (With airflow limitation): N = 352, P-linearity = 0.02,
P-nonlinearity<0.001. The increase in LV EDV seen at lower values of TPVV flattens after adjustment for LV ejection fraction.
https://doi.org/10.1371/journal.pone.0176180.g002
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and fully-adjusted analyses (OR 1.24/SD TPVV; P-value = 0.02). The association between
TPVV and dyspnea was also modified by smoking history (P-interaction = 0.03).
Among ever-smokers, a lower TPVV was associated with dyspnea and wheezing indepen-
dent of lung function, percent emphysema and LV ejection fraction (Table 3). Associations of
TPVV with dyspnea and wheezing persisted among ever-smokers without airflow limitation
or emphysema (dyspnea: OR 1.55/SD TPVV, P-value = 0.01; wheezing: OR 1.75/SD TPVV,
P-value = 0.01). There were no associations between TPVV and respiratory symptoms among
never-smokers in adjusted models.
Discussion
In this large, population-based study, a lower pulmonary vascular volume was associated with
decrements in left atrial volumes, LV end-diastolic volume, stroke volume and cardiac output,
and with dyspnea among persons who had smoked more than 100 lifetime cigarettes, includ-
ing those without demonstrable smoking-related lung disease. These findings suggest that sub-
tle changes in the pulmonary vasculature–which are generally unobserved in clinical practice–
may impair LV filling and contribute to respiratory symptoms in ever-smokers in the general
population in the absence of impaired LV relaxation.
This is the first study of which we are aware to assess the pulmonary vasculature, cardiac
function and dyspnea in a population-based sample. Small studies have correlated pulmonary
blood volume with cardiac output and LV stroke volume in valvular heart disease [40, 41], and
with LV end-diastolic volume index in severe emphysema [42]. Dyspnea on exertion has been
attributed to the inability to augment pulmonary blood flow during exercise in pulmonary
arterial hypertension [43, 44] and tricuspid regurgitation [45]. In addition, a lower volume of
small pulmonary vessels on CT was correlated with reduced six minute walk distance in smok-
ers, most of whom had COPD [10].
A potential mechanism for these findings is diffuse, smoking-related pulmonary microvas-
cular damage leading to reduced pulmonary blood flow, causing reduced inflow to the LV.
Smaller pulmonary capillary volumes are seen in smoke-exposed animals [46] and pulmonary
Table 3. Association of respiratory symptoms with 1 standard deviation lower total pulmonary vascular volume stratified by smoking history.
Ever-smokers
(N = 1226)
Odds Ratio (95% CI)
P-value Never-smokers
(N = 1074)
Odds Ratio (95% CI)
P-value
Dyspneaa
Unadjusted 1.61 (1.40, 1.85) <0.001 1.37 (1.17, 1.62) <0.001
Model 1 1.58 (1.28, 1.94) <0.001 1.03 (0.80, 1.34) 0.80
Model 2 1.46 (1.15, 1.85) 0.002 0.92 (0.69, 1.23) 0.58
Wheezing
Unadjusted 1.35 (1.14, 1.59) <0.001 1.34 (1.04, 1.73) 0.03
Model 1 1.59 (1.24, 2.04) <0.001 1.14 (0.77, 1.69) 0.51
Model 2 1.41 (1.06, 1.87) 0.02 0.89 (0.56, 1.40) 0.61
Chronic cough
Unadjusted 1.09 (0.91, 1.30) 0.36 1.15 (0.90, 1.46) 0.26
Model 1 1.00 (0.76, 1.32) 0.997 1.06 (0.71, 1.56) 0.79
Model 2 0.94 (0.69, 1.28) 0.69 0.85 (0.55, 1.33) 0.49
Model 1: adjusted for age, sex, race/ethnicity, height, weight, CT manufacturer and milliamperes, and current smoking and pack-years for ever-smokers.
Model 2: additionally adjusted for percent predicted FEV1, percent emphysema and LV ejection fraction
a Dyspnea was reported for 1222 ever-smokers and 1065 never-smokers.
https://doi.org/10.1371/journal.pone.0176180.t003
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arterial remodeling occurs in smokers [47]. As the pulmonary circulation accommodates high
blood flow (~5–6 L/minute) over a low pressure gradient (~10 mmHg), minor but diffuse
damage to the pulmonary vasculature may reduce blood flow to the left heart. Another possi-
bility is that other smoking-related pulmonary changes, such as small airways disease-associ-
ated hyperinflation compressing the pulmonary vasculature [29, 48], or regional hypoxic
vasoconstriction [49], may have contributed to the findings.
An alternative hypothesis is that the association of TPVV with reduced LV filling was due
to increased LV stiffness with increased LV end-diastolic pressure (i.e., impaired LV relaxation
or “diastolic dysfunction”). A lower TPVV was associated with concentric LV remodeling (i.e.,
greater LV mass/end-diastolic volume ratio), which suggests impaired LV relaxation [50],
however, this finding was due exclusively to the decrement in LV end-diastolic volume. Addi-
tionally, a lower TPVV was associated with a lower, not greater, left atrial volume, and there
was no association with impaired LV relaxation on MRI. Furthermore, reduced LV filling due
to LV stiffness would be expected to increase pulmonary blood volume, not decrease it. Finally,
a lower pulmonary microvascular blood volume was associated with smaller pulmonary veins,
further suggesting low-to-normal LV end-diastolic pressures, and no signs of impaired LV
relaxation on MRI. Hence, the finding for LV concentric remodeling is likely a false positive
sign for impaired LV relaxation in this setting. In conjunction with dyspnea in some patients,
this finding could be mistakenly attributed to HFpEF.
Nonetheless, the findings of a shorter 25-minute post-contrast T1 time and greater extracel-
lular volume fraction suggest that those with a lower TPVV have greater myocardial fibrosis.
While LV fibrosis occurs in HFpEF and correlates with LV stiffness [51], one study found a
parallel reduction in myocardial microvascular density [52] suggesting that LV fibrosis may be
secondary to systemic microvascular damage seen in smokers [53, 54]. Nevertheless, the
cumulative results from our general population sample suggest that a lower TPVV is associated
with a phenotype of impaired cardiac filling without an increase in LV end-diastolic pressure
(and thus distinct from HFpEF); the potential contribution of LV fibrosis to this phenotype
deserves further study.
Notably, the association between TPVV and LV filling was independent of measured lung
function, percent emphysema and high attenuation areas on CT and was present among par-
ticipants without functional or structural evidence of smoking-related lung disease. These
findings suggest that smoking-related changes in the pulmonary vasculature might contribute
to impaired cardiac filling and dyspnea independent of, and in the absence of, lung disease.
This may have potential implications for disease prevention, as some early pulmonary vascular
changes appear reversible [55].
A lower TPVV was associated with decrements in LV end-diastolic volume even among
participants who had smoked 0–10 pack-years. This suggests a risk to the pulmonary vascula-
ture associated with a smoking history that is usually considered insignificant for smoking-
related lung disease, but is consistent with increased cardiovascular risk observed in light and
intermittent smokers [56].
Strengths of this study include the use of novel quantitative pulmonary vascular measures
in a large, multiethnic, general population sample, MRI measures of cardiac structure and
function, and precise measures of potential confounders. However, several limitations should
be discussed.
First, the TPVV was measured on non-contrast CT and did not assess the microvasculature,
pulmonary arterial pressure or flow, and was not validated against invasive measures and is
not yet measured in clinical practice. While invasive measures were not feasible in a sample
this large, findings were confirmed in a second sample with direct measures of pulmonary
microvascular blood volume obtained on contrast-enhanced MRI, measures that were
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consistent with global lung perfusion and correlated with diffusing capacity [57]. While diffus-
ing capacity was not measured in the larger cohort, it has limited utility for this study as a mea-
sure of the pulmonary vasculature as it would be expected to be low with both pulmonary
vascular damage and subclinical diastolic dysfunction. Additionally, mean values of TPVV are
approximately 25–30% of the pulmonary blood volume measured invasively; this difference is
not unexpected, given the included and detectable vessels. While measurement of pulmonary
blood volume is not feasible in current practice, the findings in this paper suggest further stud-
ies focusing on the pulmonary vasculature as a therapeutic target in HFpEF may be warranted.
Second, TPVV was higher in ever-smokers compared to never-smokers instead of lower as
would be expected with the hypothesized microvascular damage incurred by smoking. However,
this was largely due to differences in body size, as percent TPVV, normalized to lung volume,
tended to be lower in ever-smokers compared to never-smokers. While the microvasculature
itself is not included in the TPVV, and we are not able to differentiate arterial from venous vol-
umes, the described associations with a lower TPVV likely reflect a simultaneous reduction in
arterial, venous and microvascular volumes.
Third, echocardiography, commonly used to assess diastolic function of the LV, and dia-
stolic stress tests were not performed. However, MRI measures of impaired LV relaxation
directly measure strain and predict clinical events [25]. Additionally, results for left atrial vol-
ume and pulmonary vein area suggest reduced rather than elevated LV end-diastolic pressure,
consistent with the lower estimated left atrial pressure described in COPD [58]. Systemic arte-
rial stiffness, which has been associated with cigarette smoking [59], greater emphysema in
COPD [60] and with HFpEF [61, 62] was also not examined, although given the direction of
blood flow it would be unlikely for systemic arterial stiffness to alter pulmonary vascular
volumes.
Fourth, we were unable to assess the etiology of reduced TPVV or distinguish whether
reductions were related to vessel loss, hyperinflation-related compression, hypoxic pulmonary
vasoconstriction or RV dysfunction. RV measures were unavailable for the full cohort at this
exam, however, RV volumes have been found to be reduced in COPD [27], and were inversely
associated with percent emphysema [63] and dyspnea in MESA [64]. Importantly, adjustment
for RV measures in the second cohort did not impact the results, suggesting that a smaller RV
did not account for the findings. Reduced pulmonary artery distensibility has also been found
with increasing severity of COPD [65], a finding that could parallel the reduction in TPVV. Of
note, we have also found hyperinflation to be associated with increased LV mass and mass/
end-diastolic volume ratio among smokers, many with COPD [66]. However, hyperinflation
and hypoxemia are unlikely to fully explain the findings as results were strengthened after
adjustment for percent predicted total lung volume on CT, and unchanged after adjustment
for pulse oximetry and with restriction to those without evident lung disease.
Fifth, in this cross-sectional analysis, directionality is uncertain and selection bias is possi-
ble. It is unlikely that LV causes of impaired filling contributed to reductions in pulmonary
vascular volume, and results were unchanged after adjustment for LV ejection fraction. The
study was population-based and characteristics of the current sample were only modestly dif-
ferent from the overall sample, making selection bias an unlikely explanation for the results.
Finally, confounding is a concern in any observational study and residual confounding by
smoking, hypertension and body size is possible. However, major confounders were measured
precisely: current smoking was verified by urinary cotinine, blood pressure and medications
were measured directly. In addition, results were consistent using TPVV indexed to lung
volume.
In conclusion, in persons smoking more than 100 lifetime cigarettes a lower TPVV was
associated with reduced LV filling and a greater LV mass/end-diastolic volume ratio, and also
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with increased dyspnea, including among persons without smoking-related lung disease. This
suggests that subclinical pulmonary vascular damage may negatively affect cardiac filling and
function, and contribute to symptoms in the general population.
Supporting information
S1 Fig. Study population.
(TIF)
S2 Fig. Generalized additive multivariate model of relationship between total pulmonary
vascular volume and LV end-diastolic volume among ever-smokers (A) without emphy-
sema and (B) with emphysema. Results are adjusted for age, sex, race/ethnicity, height,
weight, education, CT scanner manufacturer, milliamperes, current smoking, pack-years, total
cholesterol, high-density lipoprotein cholesterol, triglycerides, hypertension, systolic blood
pressure, diabetes, fasting glucose, creatinine, diuretic use, percent predicted FEV1. (Missing
data for S2 Fig follows a single imputation approach.) Panel A (Without emphysema):
N = 1078, P-linearity<0.001, P-nonlinearity = 0.14. Panel B (With emphysema): N = 148, P-
linearity = 0.03, P-nonlinearity = 0.41.
(TIF)
S3 Fig. Multivariate mean differences in LV end-diastolic volume per standard deviation
lower total pulmonary vascular volume stratified by cumulative pack-years of smoking.
Results are adjusted for age, sex, race/ethnicity, height, weight, education, CT scanner manu-
facturer, milliamperes, total cholesterol, high-density lipoprotein cholesterol, triglycerides,
hypertension, systolic blood pressure, diabetes, fasting glucose, creatinine, diuretic use, percent
predicted FEV1 and percent emphysema, as well as current smoking status for ever-smokers.
(TIF)
S4 Fig. Sensitivity analysis for mean difference in LV end-diastolic volume (mL) per 1
standard deviation lower total pulmonary vascular volume for ever-smokers. Abbrevia-
tions: LV EF = left ventricular ejection fraction, FEV1 = forced expiratory capacity in 1 second,
FVC = forced vital capacity, ACE = angiotensin converting enzyme, ARB = angiotensin II
receptor blocker. Lung disease includes airflow limitation (FEV1/FVC<0.7), restrictive venti-
latory defect (FVC< lower limit of normal and FEV1/FVC>0.7), emphysema above the upper
limit of normal, and self-report of COPD, emphysema, asthma or pulmonary fibrosis. Results
are adjusted for age, sex, race/ethnicity, height, weight, education, CT scanner manufacturer,
milliamperes, current smoking, pack-years, total cholesterol, high-density lipoprotein choles-
terol, triglycerides, hypertension, systolic blood pressure, diabetes, fasting glucose, creatinine,
diuretic use, percent predicted FEV1 and percent emphysema. P-values for interactions: sex
0.19; race/ethnicity 0.33; age 0.34; current vs. former smoking 0.01; hypertension 0.72; diabetes
0.001; LV ejection fraction 0.34; asthma 0.63, restrictive ventilator defect 0.43; any lung disease
0.33.
(TIF)
S1 Table. Selected characteristics of MESA Exam 5 participants included and not included
in this analysis. Data are presented as no. (%) or mean±SD, except as noted. Abbreviations:
IQR, interquartile range; FEV1, forced expiratory volume in 1 second; FVC, forced vital capac-
ity; TPVV, total pulmonary vascular volume; LV, left ventricular. Among ever-smokers
reporting pack-years, 1085 included and 826 not included in this analysis. †Among those with
spirometry, 2101 included and 1021 not included in the analysis. Airflow limitation defined as
pre-bronchodilator FEV1/FVC< 0.7.
‡Among 828 participants who underwent full-lung CT
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but not cardiac MRI. §Among 797 MESA Exam 5 participants who underwent cardiac MRI
but not full-lung CT. llAmong 2170 included in this analysis. Among 1999 included and 605
not included in this analysis. ††Among 2052 included and 697 not included in this analysis.
‡‡Among 1926 included and 630 not included in this analysis.
(PDF)
S2 Table. Selected characteristics of included participants by quintile of percent total pul-
monary vascular volume. Data are presented as % or mean±SD, except as noted. Abbrevia-
tions: IQR, interquartile range; FEV1, forced expiratory volume in 1 second; FVC, forced vital
capacity; TPVV, total pulmonary vascular volume. For ever-smokers reporting pack-years,
N = 239, 211, 217, 202 and 215 across quintiles. †Airflow limitation defined as pre-bronchodi-
lator FEV1/FVC< 0.7.
(PDF)
S3 Table. Mean differences in LV parameters associated with a 1 standard deviation lower
percent total pulmonary vascular volume, stratified by smoking status. Model 1: Adjusted
for age, sex, race/ethnicity, height, weight, education, CT scanner manufacturer and milliam-
peres. Model 2: Additionally adjusted for total cholesterol, high-density lipoprotein choles-
terol, triglycerides, hypertension, systolic blood pressure, diabetes, fasting glucose, creatinine,
diuretic use, percent predicted FEV1 and percent emphysema, as well as current smoking sta-
tus and pack-years for ever-smokers. Cardiac output available for 1152 ever-smokers and
1018 never-smokers.
(PDF)
S4 Table. Mean differences in left atrial volume, peak early diastolic strain rate, strain
relaxation index, T1 time and extracellular volume fraction associated with a 1 standard
deviation lower total pulmonary vascular volume on computed tomography, stratified by
smoking status. Model 1: Adjusted for age, sex, race/ethnicity, height, weight, education, CT
scanner manufacturer and milliamperes. Model 2: Additionally adjusted for total cholesterol,
high density lipoprotein cholesterol, triglycerides, hypertension, systolic blood pressure, diabe-
tes, fasting glucose, creatinine, diuretic use, percent predicted FEV1 and percent emphysema,
as well as current smoking status and pack-years for ever-smokers. T1 time and extracellular
volume fraction models also adjusted for heart rate and left ventricular end-diastolic mass.
(PDF)
S5 Table. Characteristics of participants with LV parameters and pulmonary microvascular
blood volume measured on MRI. Data are presented as % or mean±SD, except as noted. Abbre-
viations: HDL, high-density lipoprotein; COPD, chronic obstructive pulmonary disease; GOLD,
Global initiative for chronic obstructive lung disease; IQR, interquartile range. Calculated as
pulmonary microvascular blood volume (cm3 blood/100 cm3 lung) x total lung volume on CT
scans obtained at functional residual capacity, in 91 subjects.
(PDF)
S6 Table. Mean differences in LV parameters, left atrial volume and pulmonary vein area
associated with a 1 SD lower pulmonary microvascular blood volume on MRI in an inde-
pendent sample of ever-smokers (N = 142). Abbreviations: LV, left ventricular; EDV, end-
diastolic volume. Model 1: Adjusted for age, sex, race/ethnicity, height, weight, education and
cohort. Model 2: Additionally adjusted for smoking status, pack-years, total cholesterol, high
density lipoprotein cholesterol, triglycerides, hypertension, systolic blood pressure, diabetes,
fasting glucose, creatinine, diuretic use, percent predicted FEV1 and percent emphysema.
Model 3: Additionally adjusted for respective right ventricular parameter. N = 141, 1
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participant with uninterpretable right ventricular measures on MRI. †N = 139, 3 participants
without left atrial volume or pulmonary vein area measurement. ‡Adjusted for right ventricu-
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